Olmesartan Tecnigen (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Tecnigen, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage high blood pressure in adult patients. GNH USA supplies Olmesartan Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan works primarily on the renin‑angiotensin‑aldosterone system to lower blood pressure.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

Adverse reactions reported with olmesartan are generally mild to moderate.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Bullous pemphigoid (rare skin reaction)

Olmesartan should be used with caution in several clinical situations.

- Pregnancy: contraindicated in the second and third trimesters due to risk of fetal toxicity. - Renal impairment: dose adjustment may be required; monitor kidney function. - Hyperkalemia risk: avoid concomitant potassium‑saving diuretics unless indicated. - Drug‑induced liver injury: monitor liver enzymes if patient has pre‑existing liver disease. - Elderly patients: start at lower dose and titrate slowly. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with several other medicines, requiring monitoring or avoidance.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of renal dysfunction and hyperkalaemia. - Potassium‑supplementing agents or potassium‑sparing diuretics: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Diuretics: may enhance hypotensive effect, especially at therapy initiation. - Lithium: may increase serum lithium levels, requiring dose adjustment. - Rifampin: may reduce olmesartan plasma concentrations. - CYP450 inhibitors/inducers: may modestly affect olmesartan metabolism.